The combination of SLC-PDL1 and SLC-CTLA4 led to significantly decreased tumor volumes, compared to each monotherapy, in both the CT26 and A20 tumor models, although comparison with the combination of systemic PD-L1 and CTLA-4 blockade was not performed [126]. This evidence concerns the gene CD274 and neoplasm.